# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for ...
Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.00...
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This i...
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price targe...
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Sell and lowers the price target from $...